Menu
Search
|

Menu

Close
X

Arcturus Therapeutics Ltd ARCT.OQ (NASDAQ Stock Exchange Global Market)

6.16 USD
-0.65 (-9.54%)
As of 2:29 AM IST
chart
Previous Close 6.81
Open 6.76
Volume 10,930
3m Avg Volume 5,527
Today’s High 6.76
Today’s Low 6.16
52 Week High 11.41
52 Week Low 4.80
Shares Outstanding (mil) 27.56
Market Capitalization (mil) 28.94
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.50 Mean rating from 4 analysts

KEY STATS

Revenue (mm, USD)
FY18
5
FY17
21
FY16
20
FY15
0
EPS (USD)
FY18
-1.643
FY17
-3.974
FY16
3.675
FY15
-6.249
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
33.64
Price to Sales (TTM)
vs sector
--
5.95
Price to Book (MRQ)
vs sector
0.71
4.89
Price to Cash Flow (TTM)
vs sector
--
22.90
Total Debt to Equity (MRQ)
vs sector
0.00
17.74
LT Debt to Equity (MRQ)
vs sector
0.00
13.15
Return on Investment (TTM)
vs sector
-41.68
14.22
Return on Equity (TTM)
vs sector
-41.68
15.99

EXECUTIVE LEADERSHIP

Peter Farrell
Chairman of the Board, Since 2018
Salary: --
Bonus: --
Joseph Payne
President, Chief Executive Officer, Director, Since 2018
Salary: --
Bonus: --
Andrew Sassine
Interim Chief Financial Officer, Director, Since 2018
Salary: --
Bonus: --
Pad Chivukula
Chief Operating Officer, Chief Scientific Officer, Since 2018
Salary: --
Bonus: --
Kevin Skol
Senior Vice President - Business Development & Alliance Management, Since 2018
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

10628 Science Center Dr Ste 200
SAN DIEGO   CA   92121-1128

Phone: +1858.9002660

Arcturus Therapeutics Ltd, formerly Alcobra Ltd, is an Israel-based preclinical-stage biopharmaceutical company primarily focused on the discovery, development and commercialization of ribonucleic acid (RNA) medicines using lipid-mediated nanoparticle delivery system (LUNAR) and Unlocked Nucleomonomer Agent (UNA) Oligomer chemistry technology platforms. The Company, through Arcturus Therapeutics Inc, its wholly owned subsidiary based in the United States, is focused on developing RNA medicines for rare, infectious, fibrotic and respiratory diseases with unmet medical needs, including cystic fibrosis, nonalcoholic steatohepatitis (NASH) and rare liver diseases, as well as replicon RNA vaccines.

SPONSORED STORIES